Expand NRIX Menu
NRIX MENU

NRIX Stock Posts


NRIX #NurixTherapeutics stock declines -3.9% in after hours trading. See the latest news.

After Hours Decliner

NRIX Nurix Therapeutics15.64+1.00+6.8%

After Hours:15.04-0.60 (-3.9%)

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Globe NewswireMon, 8-Jun 1:00 AM
NRIX #NurixTherapeutics stock declines -3.3% in after hours trading. See the latest news.

After Hours Decliner

NRIX Nurix Therapeutics15.64+1.00+6.8%

After Hours:15.13-0.51 (-3.3%)

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Globe NewswireMon, 8-Jun 1:00 AM
Unusual Option Volume

NRIX Nurix Therapeutics15.76+1.12 (+7.7%)

Nurix Therapeutics trades 2,074 contracts. The company has the following event: Nurix Therapeutics Conference Call and Webcast on Jun 8, 2026. News: Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
View Details...
NRIX #NurixTherapeutics stock declines -5.7% in after hours trading. See the latest news.

After Hours Decliner

NRIX Nurix Therapeutics10.86+0.88+8.8%

After Hours:10.24-0.62 (-5.7%)

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Globe NewswireThu, 9-Oct 4:01 PM
NRIX #NurixTherapeutics stock declines -5.7% in after hours trading. See the latest news.

After Hours Decliner

NRIX Nurix Therapeutics10.86+0.88+8.8%

After Hours:10.24-0.62 (-5.7%)

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Globe NewswireThu, 9-Oct 4:01 PM
Unusual Option Volume

NRIX Nurix Therapeutics22.49+1.83 (+8.9%)

Nurix Therapeutics trades 2,534 contracts. The highest volume is in the 17-Jan-25 20 calls. News: Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
View Details...
Load Earlier Posts
Market Data Delayed 15 Minutes